Tepper Joel E
Department of Radiation Oncology, UNC/Lineberger Comprehensive Cancer Center, University of North Carolina, School of Medicine, Chapel Hill, NC.
Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S2-5.
There have been very few treatment-related studies specifically addressing adenocarcinomas of the gastroesophageal junction (GEJ). Studies addressing esophageal cancer have a larger percentage of patients with GEJ adenocarcinomas than do the primary gastric trials. Studies of surgery alone have shown high local failure rates for both esophageal and gastric cancers, and for both anatomic sites the addition of radiation therapy has been shown to decrease the local failure rate and improve survival. Chemotherapy as an adjuvant to surgery has also been shown to be of value in both anatomic sites. Combining all three treatment modalities, surgery, radiation therapy, and chemotherapy, is likely to produce the best overall outcomes for patients with this disease, which is rapidly increasing in incidence.
专门针对胃食管交界部(GEJ)腺癌的治疗相关研究非常少。与原发性胃癌试验相比,针对食管癌的研究中GEJ腺癌患者的比例更高。单纯手术治疗的研究表明,食管癌和胃癌的局部失败率都很高,对于这两个解剖部位,加用放射治疗已被证明可降低局部失败率并提高生存率。化疗作为手术的辅助治疗,在这两个解剖部位也已被证明具有价值。对于这种发病率正在迅速上升的疾病,将手术、放射治疗和化疗这三种治疗方式结合起来,可能会为患者带来最佳的总体治疗效果。